National Institute for Health and Care Excellence2d
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...
National Institute for Health and Care Excellence2d
Advanced breast cancer: diagnosis and management (Partial update)
For further information on the guideline development process, please see how we develop NICE guidelines ...
National Institute for Health and Care Excellence11d
NICE and NIHR: an enduring partnership
An insight into one of NICE’s most long-standing collaborative relationships. For nearly 20 years, NICE has worked with the ...
National Institute for Health and Care Excellence10d
NICE Board says new method allowing greater weight to be given to severe diseases is working
The new modifier was introduced in 2022 to allow extra weight to be given to medicines that address severe diseases. It ...
National Institute for Health and Care Excellence3d
Make your voice heard on a NICE committee
In this episode, we hear from Professor Jonathan Benger, NICE's deputy chief executive and interim director of our Centre for Guidelines. He's joined by Dr Bryony Kendall who is a GP and sits on NICE ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
The evaluation committee considered evidence submitted by Santen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Latanoprost–netarsudil (Roclanda, Santen) is indicated 'for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...